Avantor Expands European Manufacturing to Meet Biopharmaceutical Demand and Enhance Capacity
- Avantor expanded its Gliwice, Poland facility, quadrupling production capacity for critical biopharmaceutical materials.
- The expansion supports Avantor’s commitment to high-quality product supply for the growing biopharmaceutical industry.
- Avantor inaugurated a new Innovation Center in New Jersey to enhance research and development capabilities.
Avantor Expands Manufacturing Footprint in Europe to Meet Biopharmaceutical Demand
Avantor, Inc., a prominent provider of essential products and services within the life sciences and advanced technology sectors, has successfully completed a major expansion at its primary manufacturing facility in Gliwice, Poland. This strategic enhancement significantly increases the facility's capability to produce critical biopharmaceutical materials, particularly United States Pharmacopoeia (USP) purified water and Water for Injection (WFI)-based hydration solutions. The expansion, which quadruples the production capacity, is pivotal for meeting the ever-growing demands of the biopharmaceutical industry. Ger Brophy, PhD, who leads Avantor's Scientific Advisory Board, is scheduled to present the highlights of this expansion during the upcoming Drug, Chemical & Associated Technologies Association (DCAT) Week 2025 in New York City from March 17 to 20.
Benoit Gourdier, Executive Vice President of Avantor's Bioscience Production Segment, emphasizes that the expansion not only fortifies Avantor’s global manufacturing network but also ensures a consistent supply of high-quality products. This investment underscores Avantor's commitment to being a reliable partner in the production of therapies that are vital for patient care. The expansion in Poland follows similar initiatives, including a facility upgrade in Aurora, Ohio, aimed at increasing hydration solutions capacity for the North American market, and the establishment of a new production site in Phillipsburg, New Jersey, which has doubled the output of synthesized salts essential for hydration manufacturing.
In addition to bolstering manufacturing capabilities, Avantor is also advancing its research and innovation efforts by inaugurating a new 60,000-square-foot Bridgewater Innovation Center in New Jersey. This facility enhances the company's laboratory and pilot plant capacity, facilitating collaboration and innovation across various bioprocessing stages, such as upstream and downstream development, analytical testing, and viral vector research. This expansion reflects Avantor's proactive approach to addressing the evolving needs of the biopharmaceutical industry, ensuring that it remains at the forefront of scientific and technological advancements.
Furthermore, the Gliwice expansion highlights Avantor’s strategic initiative to enhance its position in the global market, aligning with the increasing demand for high-quality biopharmaceutical products. As the industry continues to evolve, Avantor's commitment to innovation and capacity growth positions the company as a key player in supporting therapeutic development and production. With significant investments in both manufacturing and research, Avantor is well-equipped to meet future challenges and contribute to the health and wellness of patients worldwide.